lifestyle.militaryparenting.org

Author: Erasca, Inc.

Erasca Reports First Quarter 2026 Business Updates and Financial Results

May 11, 2026
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

May 11, 2026
Erasca to Present at the Bank of America Securities Health Care Conference

May 6, 2026
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

April 27, 2026
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

April 27, 2026
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

March 12, 2026